Literature DB >> 9193187

Differential effects on portal and effective hepatic blood flow. A comparison between transjugular intrahepatic portasystemic shunt and small-diameter H-graft portacaval shunt.

A S Rosemurgy1, E E Zervos, S E Goode, T J Black, B R Zwiebel.   

Abstract

OBJECTIVE: This study was undertaken to determine the effects of transjugular intrahepatic portasystemic shunt (TIPS) and small-diameter prosthetic H-graft portacaval shunt (HGPCS) on portal and effective hepatic blood flow. SUMMARY BACKGROUND DATA: Mortality after TIPS is higher than after HGPCS for bleeding varices. This higher mortality is because of hepatic failure, possibly a result of excessive diminution of hepatic blood flow.
METHODS: Forty patients randomized prospectively to undergo TIPS or HGPCS had effective hepatic blood flow determined 1 day preshunt and 5 days postshunt using low-dose galactose clearance. Portal blood flow was determined using color-flow Doppler ultrasound.
RESULTS: Treatment groups were similar in age, gender, and Child's class. Each procedure significantly reduced portal pressures and portasystemic pressure gradients. Portal flow after TIPS increased (21 mL/second +/- 11.9 to 31 mL/second +/- 16.9, p < 0.05), whereas it remained unchanged after HGPCS (26 mL/second +/- 27.7 to 14 mL/second +/- 41.1, p = n.s.). Effective hepatic blood flow was diminished significantly after TIPS (1684 mL/minute +/- 2161 to 676 mL/minute +/- 451, p < 0.05) and was unaffected by HGPCS (1901 mL/ minute +/- 1818 to 1662 mL/minute +/- 1035, p = n.s.).
CONCLUSIONS: Both TIPS and HGPCS achieved significant reductions in portal vein pressure gradients. Portal flow increased after TIPS, although most portal flow was diverted through the shunt. Effective hepatic flow is reduced significantly after TIPS but well preserved after HGPCS. Hepatic decompensation and mortality after TIPS may be because, at least in part, of reductions in nutrient hepatic flow.

Entities:  

Mesh:

Year:  1997        PMID: 9193187      PMCID: PMC1190803          DOI: 10.1097/00000658-199705000-00016

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  23 in total

1.  GALACTOSE DISAPPEARANCE FROM THE BLOOD STREAM. CALCULATION OF A GALACTOSE REMOVAL CONSTANT AND ITS APPLICATION AS A TEST FOR LIVER FUNCTION.

Authors:  H Colcher; A J Patek; F E Kendall
Journal:  J Clin Invest       Date:  1946-09       Impact factor: 14.808

2.  Two-year outcome following transjugular intrahepatic portosystemic shunt for variceal bleeding: results in 90 patients.

Authors:  J M LaBerge; K A Somberg; J R Lake; R L Gordon; R K Kerlan; N L Ascher; J P Roberts; M M Simor; C A Doherty; J Hahn
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

Review 3.  Transjugular intrahepatic portal-systemic shunts: the state of the art.

Authors:  H O Conn
Journal:  Hepatology       Date:  1993-01       Impact factor: 17.425

Review 4.  Surgical management of portal hypertension.

Authors:  J C Collins; I J Sarfeh
Journal:  West J Med       Date:  1995-06

5.  Transjugular intrahepatic portosystemic shunt in the management of variceal bleeding: indications and clinical results.

Authors:  M Martin; A B Zajko; P D Orons; G Dodd; H Wright; J Colangelo; R Tartar
Journal:  Surgery       Date:  1993-10       Impact factor: 3.982

6.  Transjugular intrahepatic portosystemic shunting: decreased survival for patients with high APACHE II scores.

Authors:  R A Rubin; Z J Haskal; C B O'Brien; C Cope; C A Brass
Journal:  Am J Gastroenterol       Date:  1995-04       Impact factor: 10.864

7.  The role of transjugular intrahepatic portosystemic shunts in the management of patients with end-stage liver disease.

Authors:  J Forster; R Delcore; K M Payne; E L Siegel
Journal:  Am J Surg       Date:  1994-12       Impact factor: 2.565

8.  Multicenter investigation of the role of transjugular intrahepatic portosystemic shunt in management of portal hypertension.

Authors:  D M Coldwell; E J Ring; C R Rees; G Zemel; M D Darcy; Z J Haskal; M A McKusick; A J Greenfield
Journal:  Radiology       Date:  1995-08       Impact factor: 11.105

9.  Diagnostic and therapeutic technology assessment. Transjugular intrahepatic portosystemic shunt (TIPS).

Authors:  R Miller-Catchpole
Journal:  JAMA       Date:  1995-06-21       Impact factor: 56.272

10.  Transjugular intrahepatic portosystemic shunt in nonliver transplant candidates: is it indicated?

Authors:  S E Spiess; T A Matalon; D M Jensen; H J Rosenblate; M C Brunner; D R Ganger
Journal:  Am J Gastroenterol       Date:  1995-08       Impact factor: 10.864

View more
  10 in total

1.  Assessment of the hepatic microvascular changes in liver cirrhosis by perfusion computed tomography.

Authors:  Mai-Lin Chen; Qing-Yu Zeng; Jian-Wei Huo; Xiao-Ming Yin; Bao-Ping Li; Jian-Xin Liu
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

Review 2.  Neuronal nitric oxide synthase and Hepatic Encephalopathy.

Authors:  V L Rao; R F Butterworth
Journal:  Metab Brain Dis       Date:  1998-09       Impact factor: 3.584

3.  Transjugular intrahepatic portosystemic shunt vs. small-diameter prosthetic H-graft portacaval shunt: extended follow-up of an expanded randomized prospective trial.

Authors:  A S Rosemurgy; F M Serafini; B R Zweibel; T J Black; B T Kudryk; H J Nord; S E Goode
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

4.  H-graft portacaval shunts versus TIPS: ten-year follow-up of a randomized trial with comparison to predicted survivals.

Authors:  Alexander S Rosemurgy; Mark Bloomston; Whalen C Clark; Donald P Thometz; Emmanuel E Zervos
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

5.  507 Warren-Zeppa distal splenorenal shunts: a 34-year experience.

Authors:  Alan S Livingstone; Leonidas G Koniaris; Eduardo A Perez; Nicholas Alvarez; Joe U Levi; Duane G Hutson
Journal:  Ann Surg       Date:  2006-06       Impact factor: 12.969

6.  Post-shunt resource consumption favors small-diameter prosthetic H-graft portacaval shunt over TIPS for patients with poor hepatic reserve.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Mark Bloomston; Alan J Durkin; Whalen C Clark; Stephanie Goff
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

7.  Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis.

Authors:  Davide Roccarina; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Amine Benmassaoud; Maria Corina Plaz Torres; Laura Iogna Prat; Mario Csenar; Sivapatham Arunan; Tanjia Begum; Elisabeth Jane Milne; Maxine Tapp; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Norman R Williams; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-06

8.  Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Danielle Roberts; Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Sivapatham Arunan; Tanjia Begum; Norman R Williams; Dana Walshaw; Elisabeth Jane Milne; Maxine Tapp; Mario Csenar; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-10

9.  Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.

Authors:  Maria Corina Plaz Torres; Lawrence Mj Best; Suzanne C Freeman; Danielle Roberts; Nicola J Cooper; Alex J Sutton; Davide Roccarina; Amine Benmassaoud; Laura Iogna Prat; Norman R Williams; Mario Csenar; Dominic Fritche; Tanjia Begum; Sivapatham Arunan; Maxine Tapp; Elisabeth Jane Milne; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-03-30

Review 10.  Malnutrition in Patients with Liver Cirrhosis.

Authors:  Julia Traub; Lisa Reiss; Benard Aliwa; Vanessa Stadlbauer
Journal:  Nutrients       Date:  2021-02-07       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.